Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus
Overview
- Phase
- Phase 4
- Intervention
- Metformin and Saxagliptin
- Conditions
- Diabetes Mellitus, Type 2
- Sponsor
- ikfe-CRO GmbH
- Enrollment
- 120
- Locations
- 7
- Primary Endpoint
- percentage of patients with stable HbA1c
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to investigate the success rate of a switch from insulin therapy to a metformin & saxagliptin combination in patients with type 2 diabetes mellitus.
Detailed Description
The following study is based on a previous clinical trial performed at ikfe GmbH in Mainz in 2006 and 2007 (PIOswitch). \[2\] The purpose of this trial was to demonstrate that type 2 diabetes patients treated with insulin can be effectively switched to a pioglitazone/glimepiride combination without loss of glycemic control. The study was performed with 100 patients, out of whom 76 were finally successfully switched, resulting in a cheaper and more convenient therapy with indications of an improved laboratory cardiovascular risk biomarker profile (Hohberg et al., Diabetes Obes. Metab. 11:464-471, 2009). \[2\] Glimeperide is an agent with unspecific stimulating effect on the ß-cell and is considered to accelerate the progression of the disease while still controlling blood glucose. In addition, it may cause hypoglycemia. The combination of pioglitazone with glimepiride was selected, because pioglitazone requires approx. 5-6 weeks for developing its full anti-diabetic efficacy and an immediate effect on glucose was required to avoid glycemic deterioration. It is tempting to speculate that the combination of a drug providing ß-cell protection (like saxagliptin) with a drug effectively and rapidly lowering blood glucose through a different mechanism of action (metformin) instead of unspecific ß-cell stimulation would result in an even improved outcome without risk of hypoglycemia. The purpose of this study is to investigate the success rate of a switch from insulin therapy to a metformin \& saxagliptin combination in patients with type 2 diabetes mellitus.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Combination of OAD and basal insulin treatment (BOT) or intensified conventional therapy (ICT; \> 2 injections of basal and prandial) or conventional insulin therapy (CIT; 1 or 2 injections of basal or biphasic)
- •HbA1c \< 7.5 %
- •Age: 18-80 years inclusively
- •Duration of insulin therapy \> 1 year
- •Insulin dose \< 120 IU/day
- •Fasting C-peptide \> 0.6 ng/l
- •Fasting glucose ≤ 210 mg/dl
- •Full legal, mental and physical ability to give informed consent
- •Patient consent that the general physician will be informed of trail participation
- •Experience in self measurement of blood glucose \> 1 year
Exclusion Criteria
- •Type 1 Diabetes mellitus
- •History of drug or alcohol abuse within the last five years prior to screening
- •History of severe or multiple allergies
- •Progressive fatal disease
- •History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT and/or ASAT \> 3 times the normal reference range), neurological, psychiatric and/or haematological disease as judged by the investigator
- •Renal insufficiency or history of significant renal diseases (creatinine clearance lower than 60 ml/min determined using the Cockroft-Goult equation).
- •Contra-indications for study drugs including contraindications for the rescue drugs
- •Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures
- •Pregnancy or breast feeding
- •Sexually active women of childbearing potential not consistently and correctly practicing birth control by implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomised partner
Arms & Interventions
Saxagliptin & metformin
Saxagliptin and metformin tablets will be administered orally. Pioglitazione (Rescue medication) tablets will be administered orally. Insulin glargine (Rescue medication) will be administered via subcutaneous injection as individually prescribed.
Intervention: Metformin and Saxagliptin
Outcomes
Primary Outcomes
percentage of patients with stable HbA1c
Time Frame: 26 ± 2 weeks (baseline to postbaseline values) at 4 week intervals
Secondary Outcomes
- impact of the switch on:(26 ± 2 weeks (baseline to postbaseline values))